Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The Department of Health and Human Services intends to award a sole-source contract for nucleic acid-based reagents for in vivo transient protein expression to the University of Pennsylvania. These reagents will be used in preclinical studies to investigate preventive strategies against viral infections, ensuring consistency with previous studies.
This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only.
Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.
------------------------------------------------------------------------------------------------------------------------
The intent is to award a contract on a solesource basis for Nucleic acid–based reagents for in vivo transient protein expression for the National Cancer Institute and Center for Cancer Research to:
Trustees of The University of Pennsilvania - Penn Medicine
3451 Walnut Street
Philadelphia, PA
19104, USA
The supplies required are nucleic acid-based reagents.
The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models.
Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.
NOTICE OF INTENT - NUCLEIC ACID–BASED REAGENTS FOR IN VIVO TRANSIENT PROTEIN EXPRESSION is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.